ArticleFrontiers in oncology2020
Immune-Stromal Score Signature: Novel Prognostic Tool of the Tumor Microenvironment in Lung Adenocarcinoma.
Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Methodological quality of network meta-analyses of Chinese herbal medicine could be improved: an evidence mapping.Naunyn-Schmiedeberg's archives of pharmacology · 2026Pooled it
- A Mendelian randomization-based risk model using aging-related genes for prognosis in lung adenocarcinoma.Discover oncology · 2025Article
- Construction and validation of a regulatory T cells-based classification of renal cell carcinoma: an integrated bioinformatic analysis and clinical cohort study.Cellular oncology (Dordrecht, Netherlands) · 2025Article
- The Predictive Value of BUB1 in the Prognosis of Oral Squamous Cell Carcinoma.International dental journal · 2025Article
- Article
- Article
- Construction of a New Immune-Related Competing Endogenous RNA Network with Prognostic Value in Lung Adenocarcinoma.Molecular biotechnology · 2024Article
- Lymphocyte activation gene 3 served as a potential prognostic and immunological biomarker across various cancer types: a clinical and pan-cancer analysis.Clinical & translational immunology · 2024Article
- Construction of immune cell infiltration score model to assess prognostic ability of tumor immune environment in lung adenocarcinoma.American journal of translational research · 2023Article
- Mitochondrial Aldehyde Dehydrogenase 2 Represents a Potential Biomarker of Biochemical Recurrence in Prostate Cancer Patients.Molecules (Basel, Switzerland) · 2022Article
- Article
- Cellular and Molecular Profiling of Tumor Microenvironment and Early-Stage Lung Cancer.International journal of molecular sciences · 2022Article
- Identification of personalized neoantigen-based vaccines and immune subtype characteristic analysis of glioblastoma based on abnormal alternative splicing.American journal of cancer research · 2022Article
- Comprehensive analysis to identify GNG7 as a prognostic biomarker in lung adenocarcinoma correlating with immune infiltrates.Frontiers in genetics · 2022Article
- Combination of Tumor Mutational Burden and DNA Damage Repair Gene Mutations with Stromal/Immune Scores Improved Prognosis Stratification in Patients with Lung Adenocarcinoma.Journal of oncology · 2022Article
- Subtype Classification, Immune Infiltration, and Prognosis Analysis of Lung Adenocarcinoma Based on Pyroptosis-Related Genes.BioMed research international · 2022Article
- An ion-channel-gene-based prediction model for head and neck squamous cell carcinoma: Prognostic assessment and treatment guidance.Frontiers in immunology · 2022Article
- The Heterogeneity of Immune Cell Infiltration Landscape and Its Immunotherapeutic Implications in Hepatocellular Carcinoma.Frontiers in immunology · 2022Article
- Development and Validation of Lactate Metabolism-Related lncRNA Signature as a Prognostic Model for Lung Adenocarcinoma.Frontiers in endocrinology · 2022Article
- miR-1247-3p targets STAT5A to inhibit lung adenocarcinoma cell migration and chemotherapy resistance.Journal of Cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.